Roche Completes USD300 Million Shanghai Plant, Eyes Local Production of Eye Drug by 2028

Resumen detallado
(Yicai) Nov. 19 -- Roche has finished construction of a CNY2 billion (USD300 million) biopharmaceutical manufacturing facility in Shanghai, marking a major step in the Swiss…
(Yicai) Nov. 19 -- Roche has finished construction of a CNY2 billion (USD300 million) biopharmaceutical manufacturing facility in Shanghai, marking a major step in the Swiss pharmaceutical giant’s efforts to expand local production of innovative medicines in China.
The facility, which is Roche’s second innovative drug manufacturing base in the country, is expected to begin local production of faricimab, an injectable treatment for retinal diseases such as macular degeneration, by mid-2028 with sterile filling operations scheduled to start by the end of 2030, the Basel-based company said yesterday.
This will mark the first time a multinational pharmaceutical company has achieved localized production of large-molecule antibody-based biopharmaceuticals in China, it added.
Faricimab, which is marketed as Vabysmo, is the world's first bispecific antibody that targets both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2), helping to inhibit abnormal blood vessel growth while improving vascular stability. The drug was approved in China in December 2023 and added to the National Reimbursement Drug List in 2025.
Roche became the first multinational pharmaceutical firm to move into the Zhangjiang High-Tech Park in Shanghai in 1994. After 30 years of development, Roche now has 28 products on the market in China, covering eight fields such as oncology, infectious diseases, neuroscience and ophthalmology, according to its website.
Over the next two to five years, Roche plans to submit nearly 20 new products with more than 40 new indications for regulatory approval in China, it said. These will cover a range of therapeutic areas, including oncology and hematology, neuroscience, immunology, ophthalmology as well as cardiovascular, renal and metabolic diseases.
Going forward, Roche will use the new manufacturing facility to further prioritize local production and accelerate the rollout of more locally manufactured innovative medicines in China, including…
Inicio del artículo, extracto de Yicai Global. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.yicaiglobal.com)





